Article

Efficient inhibition of fusion inhibitor HY3000 peptide to SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants

2023-09-28

Abstract excerpt

SARS-CoV-2 continues to evolve and spread. Recently, the Omicron EG.5 lineage, bearing an additional F456L mutation in spike (S) protein compared to its ancestor XBB.1.9.2, and its sub-variant EG.5.1, which carries a further Q52H mutation, have raised concerns due to their increased prevalence and extended immune escape properties. Additionally, an alarming variant, BA.2.86, has also garnered global concern becaus...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 09a65a57-b4a3-5332-985e-dac51aee9a72
DOI: 10.1101/2023.09.28.559747

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficient inhibition of fusion inhibitor HY3000 peptide to SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variantsDOI 10.1101/2023.09.28.559747Read

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptidesSemantic proximity Read

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variantSemantic proximity Read

Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionSemantic proximity Read

In silico study identifies peptide inhibitors that negate the effect of non-synonymous mutations in major drug targets of SARS-CoV-2 variants.Semantic proximity Read

Neutralization sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodiesSemantic proximity Read

A macrocyclic peptide-based fusion inhibitor targeting SARS-CoV-2 Spike S2 subunitSemantic proximity Read

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccinesSemantic proximity Read

From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19?Semantic proximity Read

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity Read

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potentialSemantic proximity Read

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variantsSemantic proximity Read

Rationally Designed, ACE2 Mimetic Binder to the SARS Cov-2 Associated Spike Protein for COVID-19 Therapeutics and BeyondSemantic proximity Read